Departments of Urology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
Division of General Internal Medicine, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
J Urol. 2020 Jan;203(1):128-136. doi: 10.1097/JU.0000000000000471. Epub 2019 Jul 30.
To our knowledge it is unknown whether stereotactic body radiation therapy of prostate cancer is a substitute for other radiation treatments or surgery, or for expanding the pool of patients who undergo treatment instead of active surveillance.
Using SEER (Surveillance, Epidemiology, and End Results)-Medicare we identified men diagnosed with prostate cancer between 2007 and 2011. We developed physician-hospital networks by identifying the treating physician of each patient based on the primary treatment received and subsequently assigning each physician to a hospital. We examined the relative distribution of prostate cancer treatments stratified by whether stereotactic body radiation therapy was performed in a network by fitting logistic regression models with robust SEs to account for patient clustering in networks.
We identified 344 physician-hospital networks, including 30 (8.7%) and 314 (91.3%) in which stereotactic body radiation therapy was and was not performed, respectively. Networks in which that therapy was and was not done did not differ with time in the performance of robotic and radical prostatectomy, and active surveillance (all p >0.05). The relationship with intensity modulated radiation therapy did not show any consistent temporal pattern. In networks in which it was performed less intensity modulated radiation therapy was initially done but there were similar rates in later years. Brachytherapy trends differed among networks in which stereotactic body radiation therapy was vs was not performed with a lower brachytherapy rate in networks in which stereotactic body radiation therapy was done (p=0.03).
Surgery and active surveillance rates did not differ in networks in which stereotactic body radiation therapy was vs was not performed but when that therapy was done there was a lower brachytherapy rate. Stereotactic body radiation therapy may represent more of an alternative to brachytherapy than to active surveillance.
据我们所知,立体定向体部放射治疗前列腺癌是否可以替代其他放射治疗或手术,或者是否可以扩大接受治疗而不是主动监测的患者群体,目前尚不清楚。
我们使用 SEER(监测、流行病学和最终结果)-医疗保险数据库,确定了 2007 年至 2011 年间诊断患有前列腺癌的男性患者。我们通过识别每位患者的主要治疗方法所接受的治疗医生,建立了医生-医院网络,随后将每位医生分配到一家医院。我们通过拟合逻辑回归模型并使用稳健 SE 来考虑网络中患者的聚类,检查了按是否在网络中进行立体定向体部放射治疗分层的前列腺癌治疗的相对分布。
我们确定了 344 个医生-医院网络,其中 30 个(8.7%)和 314 个(91.3%)分别进行和未进行立体定向体部放射治疗。进行和未进行该治疗的网络在机器人和根治性前列腺切除术以及主动监测的执行时间上没有差异(所有 p>0.05)。与强度调制放射治疗的关系没有显示出任何一致的时间模式。在进行立体定向体部放射治疗的网络中,最初进行的强度调制放射治疗较少,但在随后的几年中,其治疗率相似。在进行和未进行立体定向体部放射治疗的网络中,近距离放射治疗的趋势存在差异,进行立体定向体部放射治疗的网络中近距离放射治疗的比例较低(p=0.03)。
在进行和未进行立体定向体部放射治疗的网络中,手术和主动监测率没有差异,但当进行该治疗时,近距离放射治疗的比例较低。立体定向体部放射治疗可能更多地替代近距离放射治疗,而不是主动监测。